[{"orgOrder":0,"company":"NOBO Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Poseltinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"NOBO Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NOBO Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NOBO Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"NOBO Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Poseltinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"NOBO Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NOBO Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NOBO Medicine \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Poseltinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          NOBO Medicine

                          Country arrow
                          Vitafoods
                          Not Confirmed

                          NOBO Medicine

                          Country arrow
                          Vitafoods
                          Not Confirmed

                          Details : Poseltinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 11, 2025

                          Lead Product(s) : Poseltinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 17, 2024

                          Lead Product(s) : Poseltinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Updated results from the phase II NP30179 study will show a fixed course of glofitamab monotherapy can deliver durable complete responses in people with heavily pre-treated aggressive lymphomas.

                          Product Name : Columvi

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 11, 2022

                          Lead Product(s) : Glofitamab,Lenalidomide,Poseltinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 04, 2017

                          Lead Product(s) : Poseltinib

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 20, 2017

                          Lead Product(s) : Poseltinib

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 11, 2015

                          Lead Product(s) : Poseltinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank